Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16807802 | 1.00 | POLG (0.62) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22678641 | 1.00 | POLG (0.62) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL6715777 | 1.00 | POLG (0.62) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL6258019 | 0.98 | POLG (0.59) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22508591 | 0.91 | P2RY2 (0.54) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18383663 | 0.91 | P2RY2 (0.53) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL21896183 | 0.90 | POLB (0.56) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL21895965 | 0.90 | POLB (0.56) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL12648719 | 0.90 | POLB (0.56) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL30237951 | 0.90 | POLB (0.56) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390479-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2024-11-28 | — | — | US | claimed |
| WO-2023212213-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2023-11-02 | — | — | WO | claimed |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | ISMAILI HICHAM MOULAY ALAOUI (CA) | 2004-12-09 | — | — | US | claimed |
| US-6784161-B2 | VIRICIDES FOR HEPATITIS C | BIOCHEM PHARMA, INC. (CA) | 2004-08-31 | — | — | US | claimed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | claimed |
| US-12636304-B2 | — | — | 2026-05-26 | — | — | US | disclosed |
| US-20260117290-A1 | METHOD FOR AMPLIFYING COMPLEMENTARY DNA STRAND | IMMUNOGENETEQS, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260034157-A1 | TOOLS TO TARGET NATURAL AND SYNTHETIC NUCLEOTIDE-SENSING PATHWAYS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-01-29 | — | — | US | disclosed |
| EP-4682269-A1 | METHOD FOR AMPLIFYING COMPLIMENTARY DNA STRAND | Immunogeneteqs, Inc. (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12516302-B2 | DNA polymerase theta mutants, methods of producing these mutants, and their uses | INSTITUT PASTEUR (FR) | 2026-01-06 | — | — | US | disclosed |
| US-20250179572-A1 | Photoactive Compounds and Methods for Biomolecule Detection and Sequencing | VIBRANT HOLDINGS, LLC | 2025-06-05 | — | — | US | disclosed |
| US-6482938-B1 | Compounds having energy transfer function and method for DNA base sequencing by using the same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-6365350-B1 | REACTING RIBONUCLEOTIDE 5'-TRIPHOSPHATES AND 3'-DEOXY NUCLEOTIDE TRIPHOSPHATES WITH RNA POLYMERASE AND DNA FRAGMENT CONTAINING A PROMOTER SEQUENCE FOR THE POLYMERASE, THEN SEPARATING THE TRANSCRIPTION PRODUCT AND SEQUENCING IT | THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| WO-2001060315-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS USING NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2001-08-23 | — | — | WO | disclosed |
| US-6265569-B1 | HAS ALKYL LINKER INCLUDING DOUBLE OR TRIPLE BOND WHICH ATTACHES FLUORESCENT MOLECULE TO NUCLEOTIDE; FOR TERMINATORS IN DNA SEQUENCING USING RNA POLYMERASES | THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1046648-A1 | 3'-DEOXYRIBONUCLEOTIDE DERIVATIVES | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 2000-10-25 | — | — | EP | disclosed |
| EP-0978569-A1 | METHOD OF DNA SEQUENCING | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 2000-02-09 | — | — | EP | disclosed |
| EP-0967219-A1 | COMPOUNDS HAVING ENERGY TRANSFER FUNCTION AND METHOD FOR DNA BASE SEQUENCING BY USING THE SAME | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 1999-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636304-B2 | — | RNMT, RNGTT, NSUN2 | POLG 1469/4885P2RY2 2861/4885P2RY4 3525/4885 |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | POLG 3028/4885P2RY2 1720/4885P2RY4 1225/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | POLG 3028/4885P2RY2 1720/4885P2RY4 1225/4885 |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | NSUN2, RNMT, RNGTT | POLG 543/4885P2RY2 496/4885P2RY4 575/4885 |
| US-20260034157-A1 | TOOLS TO TARGET NATURAL AND SYNTHETIC NUCLEOTIDE-SENSING PATHWAYS | P2RY2, P2RY1, P2RX1 | POLG 893/4885P2RY2 1/4885P2RY4 9/4885 |
| US-20260117290-A1 | METHOD FOR AMPLIFYING COMPLEMENTARY DNA STRAND | RNGTT, POLRMT, POLM | POLG 40/4885P2RY2 4666/4885P2RY4 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.